Oral Solid Dosage Drugs Remain Central
Quick Facts
Why Do Tablets and Capsules Remain Important for New Medicines?
Oral solid dosage forms include conventional tablets and capsules as well as products engineered for delayed, extended or otherwise modified release. They remain attractive because many patients can take them without injections, infusion facilities or specialized administration equipment. Solid formulations may also be easier to transport and store than products requiring refrigeration, although requirements differ by medicine.
Convenience alone does not make an oral medicine suitable for approval. Developers must show that each dose consistently delivers the intended amount of active ingredient and that the formulation performs as expected throughout its shelf life. The U.S. Food and Drug Administration evaluates evidence covering pharmaceutical quality, effectiveness and safety before determining whether a new drug's benefits outweigh its known risks.
How Can Formulation Change the Safety and Effectiveness of a Drug?
A tablet is a delivery system rather than simply compressed active ingredient. Its inactive components can influence disintegration, dissolution, stability and manufacturability. Specialized coatings may protect a drug from stomach acid or delay release until it reaches the intestine, while extended-release designs can spread exposure across a longer period.
These properties have direct clinical consequences. Crushing or splitting certain modified-release or enteric-coated products can destroy their delivery mechanism, potentially releasing the drug too quickly or at the wrong location. Patients should therefore follow the product label and consult a pharmacist before altering a tablet or opening a capsule.
What Must Manufacturers Prove Before an Oral Drug Is Approved?
For a new drug application, the FDA reviews clinical findings alongside information about the active ingredient, formulation, manufacturing process, analytical testing and proposed labeling. Regulators also assess whether the commercial product used by patients will perform consistently with the formulation evaluated during development.
After approval, quality oversight continues through manufacturing controls, inspections, adverse-event reporting and other postmarket activities. Changes involving production sites, ingredients or manufacturing methods may require supporting data because even apparently modest formulation changes can affect stability, dissolution or drug exposure.
Frequently Asked Questions
Not inherently. Safety depends on the active drug, dose, formulation, patient characteristics and route of administration. Oral products avoid injection-related risks but may cause gastrointestinal effects, interactions or variable absorption.
No. Some active ingredients are degraded in the digestive tract, absorbed poorly or require delivery patterns that an oral product cannot reliably provide. Those medicines may need injection, infusion, inhalation or another route.
Many should not be crushed because doing so can release the dose too rapidly. Patients should check the official label or ask a pharmacist before splitting, crushing or chewing any modified-release product.
References
- DCAT Value Chain Insights. Solid Dosage Drugs: Keeping Pace in New Drug Approvals. 2026.
- U.S. Food and Drug Administration. New Drug Application (NDA).
- U.S. Food and Drug Administration. Novel Drug Approvals for 2025.